Patent Profile: VM Institute of Research Receives Patent for Method of Treating Breast Cancer from www.patentdocs.org By Josh Bosman -- The U.S. Patent and Trademark Office recently issued U.S. Patent No. 8,642,270, which is entitled "Prognostic biomarkers to predict overall survival and metastatic disease in patients with triple ...
Share via E–mail | Twitter | Facebook
No Stay Pending Interlocutory Appeal of Denied Stay Pending CBM Review from docketreport.blogspot.com The court denied defendants' motion to stay pending an interlocutory appeal of the court's earlier decision to deny a motion to stay pending CBM review. "Defendants have failed to cite, and this Court is ...
Share via E–mail | Twitter | Facebook
WHO Bulletin Article On Local Pharmaceutical Manufacturing In Africa from www.ip-watch.org An article published in the March 2014 issue of the World Health Organisation Bulletin discusses the evolving issue of access to medicines in Africa.
Related Articles: Share via E–mail | Twitter | Facebook
WIPO Enforcement Committee Gains Ground As “Marketplace Of Ideas” from www.ip-watch.org World Intellectual Property Organization members this week are meeting to discuss efforts to better protect intellectual property rights worldwide, including some new proposals for discussion and an exhibition on national programmes.
Related Articles: Share via E–mail | Twitter | Facebook
Apple loses at the CAFC from ipbiz.blogspot.com In another bad day for Apple's iOS operating system, in the case
Anocora v. Apple , Ancora won its appeal and Apple lost its cross-appeal.
At the trial level, Anocora had lost on its infringement ...
Share via E–mail | Twitter | Facebook
ALJ Essex Denies Two Motions For Summary Determination In Certain Wireless Devices With 3G AND/OR 4G Capabilities (337-TA-868) from www.itcblog.com On February 19, 2014, ALJ Theodore R. Essex issued the public versions of Orders No. 94 and 95 (both dated February 4, 2014) in Certain Wireless Devices With 3G And/Or 4G Capabilities And Components ...
Share via E–mail | Twitter | Facebook